{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:35:39Z","timestamp":1774521339336,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ccm.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T14:58:51Z","timestamp":1733756331000},"page":"37-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Host-Directed Adjunctive Therapies in Immunocompromised Patients with Pneumonia"],"prefix":"10.1016","volume":"46","author":[{"given":"Matthew K.","family":"Hensley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Dela Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.ccm.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12913-018-3861-8","article-title":"Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer","volume":"19","author":"Schmedt","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.ccm.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1513\/AnnalsATS.201304-097OC","article-title":"Pneumonia during remission induction chemotherapy in patients with acute leukemia","volume":"10","author":"Garcia","year":"2013","journal-title":"Annals ATS"},{"key":"10.1016\/j.ccm.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"1070581","DOI":"10.3389\/fpubh.2023.1070581","article-title":"Clinical characteristics and outcomes of immunocompromised patients with severe community-acquired pneumonia: a single-center retrospective cohort study","volume":"11","author":"Wu","year":"2023","journal-title":"Front Public Health"},{"issue":"11","key":"10.1016\/j.ccm.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"ofad565","DOI":"10.1093\/ofid\/ofad565","article-title":"Community-acquired pneumonia in the immunocompromised host: epidemiology and outcomes","volume":"10","author":"Ramirez","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2024.10.003_bib7","article-title":"Added diagnostic utility of clinical metagenomics for the diagnosis of pneumonia in immunocompromised adults","author":"Azar","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1513\/AnnalsATS.202212-1019ST","article-title":"Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American thoracic society workshop report","volume":"20","author":"Cheng","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.ccm.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"e004766","DOI":"10.1136\/jitc-2022-004766","article-title":"Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies","volume":"10","author":"Rouhani","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ccm.2024.10.003_bib11","first-page":"jiad511","article-title":"Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals","author":"Haidar","year":"2023","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 vaccination in the immunocompromised study (COVICS)","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/vaccines10050800","article-title":"Vaccination for the prevention of infection among immunocompromised patients: a concise review of recent systematic reviews","volume":"10","author":"See","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ccm.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"1036658","DOI":"10.3389\/fimmu.2022.1036658","article-title":"A\u00a0therapeutic vaccine strategy to prevent Pneumocystis pneumonia in an immunocompromised host in a non-human primate model of HIV and Pneumocystis co-infection","volume":"13","author":"Rabacal","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ccm.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ccm.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"108731","DOI":"10.1016\/j.clim.2021.108731","article-title":"Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: improved understanding and new strategic approach with sargramostim","volume":"228","author":"Chu","year":"2021","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.ccm.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/314679","article-title":"Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens","volume":"179","author":"Gaviria","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"11","key":"10.1016\/j.ccm.2024.10.003_bib21","first-page":"7806","article-title":"Neutrophil CD64 expression is a predictor of mortality for patients in the intensive care unit","volume":"7","author":"Chen","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ccm.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1469-0691.2001.tb00011.x","article-title":"Granulocyte colony-stimulating factor and other cytokines in antifungal therapy","volume":"7","author":"Roilides","year":"2001","journal-title":"Clin Microbiol Infection"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000342121","article-title":"Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease","volume":"129","author":"Safdar","year":"2013","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.ccm.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"ofac535","DOI":"10.1093\/ofid\/ofac535","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) as adjuvant therapy for invasive fungal diseases","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"34","key":"10.1016\/j.ccm.2024.10.003_bib25","first-page":"3999","article-title":"Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial","volume":"33","author":"Wan","year":"2015","journal-title":"J\u00a0Clin Orthod"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.14597","article-title":"Granulocyte transfusions in the management of invasive fungal infections","volume":"177","author":"West","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ccm.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jcyt.2017.08.012","article-title":"Granulocyte transfusions: a concise review for practitioners","volume":"19","author":"Gea-Banacloche","year":"2017","journal-title":"Cytotherapy"},{"issue":"13","key":"10.1016\/j.ccm.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJM197703312961302","article-title":"A\u00a0randomized clinical trial of granulocyte transfusions for infection in acute leukemia","volume":"296","author":"Alavi","year":"1977","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1097\/MPH.0b013e31821ffdf1","article-title":"Effect and safety of granulocyte transfusions in pediatric patients with febrile neutropenia or defective granulocyte functions","volume":"33","author":"Atay","year":"2011","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ccm.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00520-002-0394-8","article-title":"Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases","volume":"11","author":"Cesaro","year":"2003","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ccm.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/0003-4819-97-4-509","article-title":"Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes","volume":"97","author":"Winston","year":"1982","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ccm.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1537-2995.1975.15676082229.x","article-title":"Granylocyte transfusion: a controlled study in patients with acuute nonlymphocytic leukemia","volume":"15","author":"Fortuny","year":"1975","journal-title":"Transfusion"},{"key":"10.1016\/j.ccm.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID\u2020 and ECMM\u2021 joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.ccm.2024.10.003_bib34","article-title":"Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction","volume":"6","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ccm.2024.10.003_bib35","first-page":"CD005339","article-title":"Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction","volume":"4","author":"Estcourt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.ccm.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/trf.13099","article-title":"Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience","volume":"55","author":"Kadri","year":"2015","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.ccm.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.seminhematol.2019.11.002","article-title":"Granulocyte transfusions: current science and perspectives","volume":"56","author":"West","year":"2019","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.ccm.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0039-1694991","article-title":"Transfusion-associated acute lung injury following donor granulocyte transfusion in two pediatric patients","volume":"8","author":"Arslan","year":"2019","journal-title":"J\u00a0Pediatr Intensive Care"},{"issue":"12","key":"10.1016\/j.ccm.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.0041-1132.2003.00568.x","article-title":"TRALI after the transfusion of cross-match-positive granulocytes","volume":"43","author":"Sachs","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.ccm.2024.10.003_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00469","article-title":"Immunomodulation for the treatment of fungal infections: opportunities and challenges","volume":"10","author":"Ademe","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ccm.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.critrevonc.2015.10.005","article-title":"Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: progress and challenges","volume":"98","author":"Papadopoulou","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.ccm.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/cti.2015.16","article-title":"Adoptive T-cell therapy for fungal infections in haematology patients","volume":"4","author":"Deo","year":"2015","journal-title":"Clin Transl Immunology"},{"issue":"13","key":"10.1016\/j.ccm.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"29","key":"10.1016\/j.ccm.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccm.2024.10.003_bib46","article-title":"Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients","volume":"bloodadvances","author":"Dadwal","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ccm.2024.10.003_bib47","author":"AlloVir"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib49","first-page":"864","article-title":"Use of monoclonal antibodies in immunocompromised patients hospitalized with severe COVID-19: a retrospective multicenter cohort","volume":"12","author":"Calder\u00f3n-Parra","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"23","key":"10.1016\/j.ccm.2024.10.003_bib50","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.ccm.2024.10.003_bib51","first-page":"e18843","article-title":"Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer","volume":"41","author":"Naser","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"10289","key":"10.1016\/j.ccm.2024.10.003_bib52","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ccm.2024.10.003_bib53","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"B\u00e9gin","year":"2021","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.ccm.2024.10.003_bib54","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ccm.2024.10.003_bib55","doi-asserted-by":"crossref","first-page":"e0858","DOI":"10.1002\/rcr2.858","article-title":"Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report","volume":"9","author":"Karaolidou","year":"2021","journal-title":"Respirol Case Rep"},{"issue":"6","key":"10.1016\/j.ccm.2024.10.003_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/infdis\/jiv143","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation and association with occurrence and outcome of invasive aspergillosis","volume":"212","author":"Stuehler","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"44","key":"10.1016\/j.ccm.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"71062","DOI":"10.18632\/oncotarget.12616","article-title":"Aspergillus fumigatus responds to natural killer (NK) cells with upregulation of stress related genes and inhibits the immunoregulatory function of NK cells","volume":"7","author":"Schneider","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccm.2024.10.003_bib59","doi-asserted-by":"crossref","first-page":"988847","DOI":"10.3389\/fmed.2022.988847","article-title":"Natural killer cell infusion for cytomegalovirus infection in pediatric patients with Wiskott-Aldrich syndrome following cord blood transplantation: a case report and literature review","volume":"9","author":"Yue","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.ccm.2024.10.003_bib60","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/v15091916","article-title":"Protective versus pathogenic type I interferon responses during virus infections","volume":"15","author":"Jung","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ccm.2024.10.003_bib61","doi-asserted-by":"crossref","first-page":"949036","DOI":"10.3389\/fcimb.2022.949036","article-title":"Superior antiviral activity of IFN\u03b2 in genital HSV-1 infection","volume":"12","author":"Schmitz","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ccm.2024.10.003_bib62","doi-asserted-by":"crossref","first-page":"1273604","DOI":"10.3389\/fimmu.2023.1273604","article-title":"Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection","volume":"14","author":"Mihaescu","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib63","doi-asserted-by":"crossref","first-page":"e0272826","DOI":"10.1371\/journal.pone.0272826","article-title":"Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Ryoo","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2024.10.003_bib64","doi-asserted-by":"crossref","first-page":"1069894","DOI":"10.3389\/fimmu.2023.1069894","article-title":"Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: a meta-analysis","volume":"14","author":"Buchynskyi","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ccm.2024.10.003_bib65","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.medj.2021.09.003","article-title":"Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series","volume":"2","author":"van Laarhoven","year":"2021","journal-title":"Med"},{"issue":"2","key":"10.1016\/j.ccm.2024.10.003_bib66","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s12325-023-02715-7","article-title":"Study protocol of a randomized controlled clinical trial to evaluate the efficacy and safety of ropeginterferon alfa-2b in COVID-19 patients with comorbidities","volume":"41","author":"Liu","year":"2024","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ccm.2024.10.003_bib67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/dna.2023.0283","article-title":"Preparing for the next pandemic: increased expression of interferon-stimulated genes after local administration of nasalferon or HeberNasvac","volume":"43","author":"Aguiar Santiago","year":"2024","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.ccm.2024.10.003_bib68","doi-asserted-by":"crossref","first-page":"156268","DOI":"10.1016\/j.cyto.2023.156268","article-title":"Cytokines and their role as immunotherapeutics and vaccine Adjuvants: the emerging concepts","volume":"169","author":"Rahman","year":"2023","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ccm.2024.10.003_bib70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2022.06.035","article-title":"Nivolumab induces long-term remission in a patient with fusariosis","volume":"173","author":"Khatamzas","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ccm.2024.10.003_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijid.2022.08.007","article-title":"Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): a randomized proof-of-concept phase II study","volume":"123","author":"S\u00e1nchez-Conde","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.ccm.2024.10.003_bib72","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"Annane","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccm.2024.10.003_bib73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccm.2024.10.003_bib74","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres","year":"2015","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.ccm.2024.10.003_bib75","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids--new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12281-023-00456-2","article-title":"The impact of corticosteroids on the outcome of fungal disease: a systematic review and meta-analysis","volume":"17","author":"Li","year":"2023","journal-title":"Curr Fungal Infect Rep"},{"issue":"21","key":"10.1016\/j.ccm.2024.10.003_bib77","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJM199011223232104","article-title":"A\u00a0controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome","volume":"323","author":"Bozzette","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11904-012-0129-5","article-title":"Management of the immune reconstitution inflammatory syndrome","volume":"9","author":"Meintjes","year":"2012","journal-title":"Curr HIV AIDS Rep"},{"key":"10.1016\/j.ccm.2024.10.003_bib80","article-title":"Dexamethasone in hospitalized patients with covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2024.10.003_bib81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","article-title":"Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials","volume":"2","author":"Calfee","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2024.10.003_bib82","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2147\/JIR.S453123","article-title":"Phenotypes and lung microbiota signatures of immunocompromised patients with pneumonia-related acute respiratory distress syndrome","volume":"17","author":"Hu","year":"2024","journal-title":"J\u00a0Inflamm Res"},{"issue":"16","key":"10.1016\/j.ccm.2024.10.003_bib83","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10229","key":"10.1016\/j.ccm.2024.10.003_bib84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ccm.2024.10.003_bib85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2024.10.003_bib86","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41375-020-0907-9","article-title":"Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)","volume":"34","author":"Neubauer","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ccm.2024.10.003_bib87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2023.07.002","article-title":"Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury","volume":"71-72","author":"Fadanni","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"10.1016\/j.ccm.2024.10.003_bib88","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cmi.2022.02.027","article-title":"Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study","volume":"28","author":"Broman","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ccm.2024.10.003_bib90","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ccm.2024.10.003_bib91","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-022-05136-x","article-title":"The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era","volume":"42","author":"Evangelatos","year":"2022","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.ccm.2024.10.003_bib92","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/bbmt.2002.v8.pm12171486","article-title":"Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Yanik","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.ccm.2024.10.003_bib93","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2008-03-143412","article-title":"The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation","volume":"112","author":"Yanik","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ccm.2024.10.003_bib94","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/blood-2014-12-617035","article-title":"Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies","volume":"125","author":"Seo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ccm.2024.10.003_bib95","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40744-021-00342-8","article-title":"TNF-\u03b1 blockers showed prophylactic effects in preventing COVID-19 in patients with rheumatoid arthritis and seronegative spondyloarthropathies: a case-control study","volume":"8","author":"Salesi","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.ccm.2024.10.003_bib96","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/ph15050616","article-title":"Immunosuppressant therapies in COVID-19: is the TNF Axis an alternative?","volume":"15","author":"Palacios","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"10.1016\/j.ccm.2024.10.003_bib97","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.3390\/ijms22168423","article-title":"Severe COVID-19 patients show an increase in soluble TNFR1 and ADAM17, with a relationship to mortality","volume":"22","author":"Palacios","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ccm.2024.10.003_bib98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2024.10.003_bib107","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ccm.2024.10.003_bib99","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cpt.3191","article-title":"Using machine learning to determine a suitable patient population for anakinra for the treatment of COVID-19 under the emergency use authorization","volume":"115","author":"Liu","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccm.2024.10.003_bib100","doi-asserted-by":"crossref","first-page":"e24096","DOI":"10.1016\/j.heliyon.2024.e24096","article-title":"Decreased risk of COVID-19 and long COVID in patients with psoriasis receiving IL-23 inhibitor: a cross-sectional cohort study from China","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.ccm.2024.10.003_bib101","doi-asserted-by":"crossref","first-page":"L925","DOI":"10.1152\/ajplung.00582.2020","article-title":"Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis","volume":"321","author":"Senoo","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib102","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.micinf.2006.10.012","article-title":"IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection","volume":"9","author":"Wu","year":"2007","journal-title":"Microb Infect"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib103","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1186\/s13063-020-04884-0","article-title":"Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Declercq","year":"2020","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ccm.2024.10.003_bib104","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1038\/s41467-018-07738-1","article-title":"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis","volume":"9","author":"Rudkin","year":"2018","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.ccm.2024.10.003_bib105","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2000024","article-title":"Disseminated coccidioidomycosis treated with interferon-\u03b3 and dupilumab","volume":"382","author":"Tsai","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ccm.2024.10.003_bib106","doi-asserted-by":"crossref","first-page":"e162290","DOI":"10.1172\/jci.insight.162290","article-title":"Blockade of TGF-\u03b2 signaling reactivates HIV-1\/SIV reservoirs and immune responses in\u00a0vivo","volume":"7","author":"Samer","year":"2023","journal-title":"JCI Insight"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523124000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523124000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:09:15Z","timestamp":1749553755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523124000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0272523124000923"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2024.10.003","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Host-Directed Adjunctive Therapies in Immunocompromised Patients with Pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}